|
ETV3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.16475751055623E-13 |
| Normal-vs-Stage2 |
9.15919999844306E-08 |
| Normal-vs-Stage3 |
1.35125244327128E-12 |
| Normal-vs-Stage4 |
1.96770044702532E-10 |
| Stage1-vs-Stage2 |
9.431800E-01 |
| Stage1-vs-Stage3 |
3.114400E-01 |
| Stage1-vs-Stage4 |
2.685200E-01 |
| Stage2-vs-Stage3 |
5.239800E-01 |
| Stage2-vs-Stage4 |
3.908200E-01 |
| Stage3-vs-Stage4 |
7.413000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.66373598126302E-14 |
| Normal-vs-AfricanAmerican |
2.388100E-04 |
| Normal-vs-Asian |
2.47360000260599E-08 |
| Caucasian-vs-AfricanAmerican |
3.629000E-01 |
| Caucasian-vs-Asian |
7.651800E-01 |
| AfricanAmerican-vs-Asian |
3.146000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.88258347483861E-15 |
| Normal-vs-Female |
1.6805445923751E-12 |
| Male-vs-Female |
8.454400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.80999676252713E-11 |
| Normal-vs-Age(41-60Yrs) |
1.06581410364015E-13 |
| Normal-vs-Age(61-80Yrs) |
1.13990039629641E-10 |
| Normal-vs-Age(81-100Yrs) |
4.096100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.607200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.700600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.123800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.129400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.560200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.084200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.944400E-03 |
| Classical-VS-Follicular |
1.303530E-02 |
| Classical-VS-Other |
4.462500E-03 |
| Classical-VS-Normal |
6.27742302583556E-12 |
| Tall-VS-Follicular |
4.467600E-01 |
| Tall-VS-Other |
2.522000E-01 |
| Tall-VS-Normal |
2.21369589326059E-11 |
| Follicular-VS-Other |
2.275800E-01 |
| Follicular-VS-Normal |
2.7716717809767E-12 |
| Other-VS-Normal |
1.01499999960453E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.04360964314765E-14 |
| Normal-vs-N1 |
8.82429684878616E-11 |
| N0-vs-N1 |
2.884400E-01 |
|
|
